Mayo Clinic develops precision medicine genomic diagnostic test for lymphoma
The Mayo Clinic announced that it has developed a new test to help with diagnosis and treatment for patients with diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma. The Lymph2Cx test helps verify where the lymphoma started by assigning “cell-of-origin” groups using a 20-gene expression-based assay, according to the Mayo Clinic.
"Diagnostic tests such as the Lymph2Cx test will address an unmet need of cancer patients in the U.S. and worldwide,” said Keith Stewart, MD, the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine.
Mayo Clinic said it will be the first site in the country to offer this test to patients. More than 20,000 people in the U.S. are diagnosed with diffuse large B-cell lymphoma each year, the clinic said.
“New tests like this help us identify accurate diagnoses and treatments quickly, saving time and money, and, ultimately, transforming patient care,” Dr. Stewart said.
[Precision medicine special report: Analytics, EHRs and data science in the new age]
The Lymph2Cx test was developed by the Lymphoma/Leukemia Molecular Profiling Project. The test is important for prognosis, choice of therapy, and achieving the best outcomes possible for patients with diffuse large B-cell lymphoma, according to co-inventor Lisa Rimsza, MD, a pathologist and director of the Molecular Diagnostic Arizona Laboratory.
“This test will accurately provide cell-of-origin information, with a rapid in-laboratory turnaround time,” Rimsza said. “The application of this test will enable more accurate molecular subtyping and prognostic evaluation of patients with diffuse large B-cell lymphoma, and allow for prospective selection of patients for subtype-specific therapeutic clinical trials.”
It is the first test to go into the Mayo practice from the new Mayo Clinic Molecular Diagnostic Arizona Laboratory. The lab enables Mayo physicians and researchers to access new and existing tests rapidly to improve patient care.
The lymphoma test will first be available to patients at Mayo’s Arizona campus, soon to be followed by the Florida and Minnesota campuses.
The Molecular Diagnostic Arizona Laboratory is a result of a collaborative development project between the Mayo Clinic Department of Laboratory Medicine and Pathology in Arizona, Research leadership in Arizona, and the Mayo Clinic Center for Individualized Medicine.